Nicholas Bodor

Nicholas Bodor Ph.D.

Graduate Research Professor Emeritus

Department: Pharmaceutics
Business Email: bodor@cop.ufl.edu

About Nicholas Bodor

Bodor received his B.S./M.S. degree in Organic Chemistry in 1959 at Bolyai University in Transylvania, and his Ph.D. degree in 1965 from the University of Babes-Bolyai, Cluj and the Romanian National Academy of Sciences. He was a Group Leader at the Pharmacochemical Research Institute in Romania until 1968, when he received a R. A. Welch Fellowship at the University of Texas in Austin. In 1972 he became a Senior Research Scientist at ALZA Laboratories in Lawrence, Kansas, which later became INTERx Research Corporation, where he was Director of Research, as well as an Adjunct Professor at the University of Kansas until 1978.

Bodor joined the University of Florida in Gainesville in 1979 as Professor and Chairman of the Medicinal Chemistry Department. He was promoted to Graduate Research Professor of the university in 1983. He is the Executive Director of the Center for Drug Discovery in the College of Pharmacy. He also holds appointments as Affiliate Graduate Research Professor in the Department of Chemistry in the College of Liberal Arts and the Department of Ophthalmology in the College of Medicine at the University. During his tenure at the University of Florida, he has supervised the training of more than 50 doctoral students and over 100 postdoctoral level research associates and fellows. In February 2000, he took a leave of absence from his academic posts at UF to accept a position as Senior Vice President of Basic Research and Drug Discovery at the IVAX Corporation. Bodor served as Chief Scientific Officer of the IVAX Corporation, Managing Director of the IVAX Drug Research Institute, Budapest, Hungary, as well as President of the IVAX Research Institute until October 2005, when he returned to the University of Florida as Graduate Research Professor and Executive Director of the Center for Drug Discovery.

Inducted into the American chemical Society’s Hall of Fame, Division of Medicinal Chemistry.

He is an elected Fellow of the Academy of Pharmaceutical Sciences, the American Association of Pharmaceutical Scientists, the American Association for the Advancement of Science, and American College of Clinical Pharmacology. He is also an Honorary Member of the Hungarian Chemical Society and the Panhellenic Society of Pharmacists. Among other honors, Dr. Bodor has been named “The 1984 Florida Scientist of the Year” and received the first AAPS Research Achievement Award in Medicinal and Natural Product Chemistry in 1988, as well as the APhA Research Achievement Award in Pharmaceutical and Medicinal Chemistry in 1989. In 1989 he also received an honorary Doctor of Science degree from the Technical University of Budapest, and then was awarded the Doctor Honoris Causa degree from the Medical University of Debrecen in 1990. In 1994 he was named the first recipient of the Nagai Foundation Tokyo International Fellowship. In 1995 he was elected to the Hungarian National Academy of Sciences. He was named by the American Chemical Society as the 1996 recipient of the Leo Friend Award in recognition of his article entitled, “Design of Biologically Safer Chemicals,” published in Chemtech, October 1995. He is the first College of Pharmacy faculty member to receive a Professorial Excellence Award, given by the University of Florida in 1996. The AACP selected Dr. Bodor as the recipient of the 1997 Volwiler Research Achievement Award. In April 2000, Bodor was named the V. Ravi Chandran Professor in Drug Design and Targeting of the UF College of Pharmacy, the first recipient of this endowed professorship. In February 2002, he was elected a Fellow of the World Innovation Foundation. In 2004, Ferenc Madl, President of Hungary, awarded Bodor the Gold Cross of Merit of the Hungarian Republic. An honorary Doctor of Science degree was conferred upon Bodor by the University of Florida in 2005. In 2007, the American Association of Pharmaceutical Scientists awarded Bodor with a Distinguished Pharmaceutical Scientist Award.

Research Profile

Bodor’s main research interests include design of drugs with improved therapeutic index, design of new chemical delivery systems, computer-assisted drug design, drug transport and metabolism, and theoretical and mechanistic organic chemistry. He has published more than 500 research articles, holds more than 180 patents, and is on the editorial boards of several international scientific journals. Bodor is the founder and organizer of a biennial series of symposia entitled, The Retrometabolism Based Drug Design and Targeting Conference, which is dedicated to the study of the drug optimization strategies that he has pioneered. The soft steroid Loteprednol Etabonate, he designed, is on the market in the U.S. and other countries. Other drugs he has designed using the retrometabolic concepts are in advanced clinical development.

Publications

Grants

January 2006 – December 2007
TXK 023-003
NOVEN PHARMACEUTICALS · Principal Investigator

Patents

Issued October 2006
Compounds and Method for the Prevention and Treatment of Diabetic Retinopathy (CON)
7,115,566
Issued September 2005
Compounds and Method for the Prevention and Treatment of Diabetic Retinopathy (DIV)
6,943,145
Issued August 2002
Compounds and Method For The Prevention and Treatment of Diabetic Retinopathy
6,440,933
Issued April 1999
Computer-Aided Retrometabolic Drug Design
TX-916-779
Issued April 1999
Molecular Size-Based Approach to Estimate LOGP
TX-916-774
Issued June 1997
Redox Amino Acids and Peptides Containing Them Sustained Delivery of Pharmacologically Active Peptides to Brain
5,639,885
Issued June 1997
Anticholinergic Compounds, Compositions and Methods of Treatment Antiperspirant, Mydriatic, Antisecretory Agents
5,637,601
Issued April 1997
Brain-enhanced Delivery of Neuroactive Peptides by Sequential Metabolism
5,624,894
Issued April 1997
Anticholinergic Compounds, Compositions and Methods of Treatment
5,618,826
Issued April 1997
Targeted Drug Delivery via Phosphonate Derivatives to Brain
5,618,803
Issued March 1997
Anticholinergic Compounds, Compositions and Methods of Treatment Mydriatics, Antiperspirants
5,610,188
Issued June 1996
Brain-specific Drug Delivery Analgesic or Narcotic Antagonist (DIV)
5,525,727
Issued May 1995
Anticholinergic Compounds, Compositions and Methods of Treatment Antiperspirants, Mydriatic
5,418,244
Issued May 1995
Targeted Drug Delivery via Phosphonate Derivatives Delivery of Steroid Sex Hormone or Antiinflammatory Steroid to the Brain
5,413,996
Issued February 1995
Redox Carriers for Brain-specific Drug Delivery
5,389,623
Issued March 1994
Brain-specific Analogues of Centrally Acting Amines Antidepressant
5,296,483
Issued November 1993
Anticholinergic Compounds, Compositions and Methods of Treatment Antisecretory Agents, Mydriatic Agents and Antiperspirants
5,258,388
Issued July 1993
Method of Improving Oral Bioavailability of Carbamazepine Anticonvulsants for Nervous System Disorders
5,231,089
Issued June 1993
Anticholinergic Compounds, Composititons and Methods of Treatment Antisecretory Agents, Mydriatics, Antiperspirants
5,223,528
Issued February 1993
Brain-specific Drug Delivery Sustained Delivery of Viricides
5,187,158
Issued January 1993
Targeted Drug Delivery via Phosphonate Derivatives
5,177,064
Issued October 1992
Compounds for Site-enhanced Delivery of Radionuclides Using a Dihydropyridine-pyridinium Salt Type of Redox Delivery; Chelate Compounds; Brain Disorders; Scintigraphy
5,155,227
Issued August 1992
Radiopharmaceuticals and Chelating Agents Useful in Their Preparation Penetration Og Blood Brain Barrier (DIV)
5,136,038
Issued June 1992
Redox Systems for Brain-Targeted Drug Delivery CASE-020
619788
Issued February 1992
Redox Carriers for Brain-specific Drug Delivery Antiviral, Anticancer, Antitumor Agents
5,087,618
Issued January 1992
Brain-Specific Analogues of Centrally…
5,082,853
Issued January 1992
Quarternary Pyridinium Salts to Derivatize Pharmaceutical Peptides for Transport Across the Blood/brain Barrier
5,079,366
Issued October 1991
NMR-Assayable Ligand-labelled Trifluorothymidine Containing Composition And Method for Diagnosis of HSV Infection
5,053,215
Issued June 1991
Pharmaceutical Formulations for Parenteral Use Administering in Aqueous Solution with Cyclodextrin Derivative
5,024,998
Issued May 1991
Redox Systems for Brain-targeted Drug Delivery (CIP)
5,017,566
Issued May 1991
Labile Derivatives of Ketone Analogs of 3-substituted-1-alkylamino-2-propanols and Their Use as Beta-adrenergic Blockers Treatment of Glaucoma
5,017,618
Issued April 1991
Brain-specific Drug Delivery Penicillin or Cephalosporin Antibiotics
5,008,257
Issued March 1991
Improvements in Redox Systems for Brain-targeted Drug Delivery Inclusion Complexing Hydroxypropylcyclodextrin with a Dihydropyridine-substituted Drug
5,002,935
Issued January 1991
Pharmaceutical Formulations for Parenteral Use Decreasing Precipitation At Injection Site or in Lungs or Other Organs by Combining with Hydroxypropyl-beta-cyclodextrin
4,983,586
Issued October 1990
Compounds for Site-enhanced Delivery of Radionuclides and Uses Thereof Increased Concentration in Brain; Medical Diagnosis
4,963,688
Issued October 1990
Novel Radiopharmaceuticals and Chelating Agents Useful in Their Preparation Dihydropyridine-pyridinium Salt Redox System for Drug Delivery in the Brain
4,963,682
Issued June 1990
Brain-specific Analogues of Centrally Acting Amines
4,933,438
Issued February 1990
Brain-specific Drug Delivery of Steroid Sex Hormones Cleaved from Pyridinium Carboxylates and Dihydro-pyridine Carboxylate Precursors
4,900,837
Issued January 1990
Composition and Method for Enhancing Permeability of Topical Drugs Choline Ester and Fatty Acid
4,892,737
Issued December 1989
Amino Acids Containing Dihydropyridine Ring Systems for Site-specific Delivery of Peptides to the Brain Dihydropyridine-pyridinium Salt Redox System
4,888,427
Issued November 1989
Brain-specific Delivery of Dopamine Utilizing Dihydropyridine/pyridinium Salt-type Redox Carriers
4,880,816
Issued November 1989
Brain-specific Drug Delivery Antiinflammatory Steroids Residue Coupled To a Carrier Comprising a Carbonyl-substituted 1-alkyldihydropyridine Biooxidizable to a Pyridinium Salt
4,880,921
Issued September 1989
Method for Treating Male Sexual Dysfunction
4,863,911
Issued May 1989
Novel Redox Carriers for Brain-specific Drug Delivery Prodrug for Sustained Release of Dopamine
4,829,070
Issued April 1989
Brain-specific Drug Delivery Dihydropyridine-pyridinium Salt Redox Carrier
4,824,850
Issued January 1989
Certain Inositol-nicotinate Ester Derivatives and Polyionic Complexes Therefore Useful for Treating Diabetes Mellitus, Hyperlipidemia and Lactic Acidosis
4,801,597
Issued September 1988
Brain-Specific Analogues of Centrally Acting Amines
4,771,059
Issued February 1988
Brain-specific Dopaminergic Activity Involving Dihydropyridine Carboxamides, Dihydroquinoline and Isoquinoline Carboxamides
4,727,079
Issued February 1988
Brain-Specific Dopaminergic Activity Involving Dihydropyridine Carboxamides, Dihydroquinoline and Isoquinoline Carboxamides
4,727,079
Issued November 1986
Testicular-specific Drug Delivery
4,622,218
Issued October 1986
Method and Compositions for Weight Control Steroids
4,617,298
Issued September 1985
Brain-specific Drug Delivery Dihydropyridine And/or Pyridinium Salt Redox Carrier
4,540,564
Issued October 1984
Brain-specific Drug Delivery Dihydropyridine Pyridinium Salt Redox Carrier
4,479,932